Updated:
Molbio Diagnostics
Molbio Diagnostics co-founder Sriram Nararajan deploys portable PCR platforms across 40 countries, scaling TB testing in India's public health system.
Molbio Diagnostics
Molbio Diagnostics was founded in 2000 by Sriram Natarajan and Chandrasekhar Nair in Goa, India. The company emerged from a deep frustration with the infrastructure required for traditional polymerase chain reaction testing, which confined molecular diagnostics to well-equipped urban laboratories. Their mission consolidated around a simple, transformative idea: shrink the entire PCR lab into a single rugged device that a frontline health worker could operate with minimal training, directly at the point of care. Molbio's strategy centers on its proprietary Truenat platform, a chip-based, portable molecular diagnostics system covering infectious diseases including tuberculosis, hepatitis, Covid-19, and vector-borne illnesses. The firm deploys through a razor-and-blade model, selling instruments to governments and hospitals while generating recurring revenue from disease-specific test kits. Its flagship TB program, executed in partnership with India's National Tuberculosis Elimination Programme, scaled to over 6,000 installed machines nationwide. Molbio has also distributed platforms into more than 40 countries across Asia, Africa, and Latin America. Key assay targets include multi-drug-resistant tuberculosis, hepatitis C, dengue, and HPV. The company serves as a principal supplier to the World Health Organization's End TB Strategy and the Indian Council of Medical Research. Backed by Singapore's Temasek Holdings, which invested approximately $85 million in 2022 at a valuation near $1.5 billion, Molbio operates a manufacturing plant in Verna, Goa, with a monthly production capacity exceeding three million tests. The September 2022 Temasek transaction established Molbio as one of India's diagnostics unicorns. In addition to its manufacturing core, Molbio runs a specialized research unit focused on assay development and a training academy for technicians. The company has not launched separate philanthropic foundations but integrates its testing infrastructure into state-run primary health centers across India, making it an operational backbone rather than a grant-making entity. Molbio's structural differentiator is its closed-system, chip-based micro-PCR technology, which eliminates the need for three-phase power, cold-chain logistics, and skilled lab personnel — a design rooted in the constraints of India's remotest primary health centers. This architecture makes the platform uniquely scalable in low-resource settings and locks in demand through exclusive, disease-specific test cartridges. All assay design and chip manufacturing remain in-house, a vertically integrated model rare in the diagnostics industry and one that gives Molbio control over cost, supply, and the speed of new test deployment for emerging pathogens.
General information
Firm type
Asset Manager
Year founded
2000
AUM
Undisclosed
Location
Region
Asia
Country
India
City
Verna
Corporate office
Verna, Goa, India
Principals
Sriram Natarajan
Founder & CEO
Chandrasekhar Nair
Founder & CTO
Sector focus
Frequently asked questions
Who runs investment decisions and product strategy at Molbio Diagnostics?
Sriram Natarajan serves as Founder and CEO, leading commercial strategy, fundraising, and government partnerships. Chandrasekhar Nair operates as Founder and Chief Technology Officer, directing the firm's micro-PCR chip design and assay development. The two founders have jointly steered the company since 2000 without introducing an external professional management layer.
How does Molbio Diagnostics source revenue, and who are its largest customers?
Molbio generates revenue through instrument sales and recurring test-kit purchases. The Government of India represents its largest customer, primarily through the National Tuberculosis Elimination Programme, which accounts for the bulk of the 6,000-plus installed Truenat machines. The company also sells into state health ministries across India and distributes internationally via aid-agency tenders and public-health procurement channels in over 40 developing countries.
What makes the Truenat platform different from a standard benchtop PCR machine?
Truenat operates on a micro-PCR chip powered by a rechargeable battery, running a full molecular test cycle in under an hour without requiring air conditioning, three-phase electricity, or cold-chain reagents. The system uses disease-specific cartridges, preventing cross-contamination and allowing a single device to run TB, hepatitis, dengue, and Covid-19 tests sequentially. This geometry means a rural health worker can run the device at a roadside clinic, whereas competing platforms from Cepheid or Roche demand stable lab infrastructure.
Does Molbio Diagnostics take external capital, and is it a family office?
Molbio is a diagnostics manufacturing and distribution business, not a family office. It raised growth equity from Temasek Holdings in 2022 in a transaction that valued the company at roughly $1.5 billion. The founders did not build the firm around a single family's wealth; it operates as a private, venture-backed operating company governed by its founding duo.
Which diseases does Molbio Diagnostics explicitly focus on, and does it avoid any major segments?
Molbio focuses squarely on infectious diseases — tuberculosis, hepatitis B and C, dengue, chikungunya, HPV, and respiratory pathogens. The firm has publicly avoided entering the non-communicable disease market, such as oncology or cardiovascular biomarkers, even though its platform could theoretically support those assays. Management has stated its prioritization is driven by the burden of infectious disease in its target public-health markets.
What is Molbio's relationship with the World Health Organization and the Indian government's TB program?
Molbio serves as a primary supplier of molecular TB diagnostics to India's National Tuberculosis Elimination Programme, which deploys Truenat machines at district and sub-district levels to replace sputum-smear microscopy. The World Health Organization endorsed Truenat as a rapid molecular test for TB in 2020, qualifying it for procurement through major global health funders including the Global Fund and Stop TB Partnership. This endorsement effectively integrates Molbio into the standard-of-care testing algorithm for TB in WHO member states.
How does Molbio Diagnostics manufacture and protect its supply chain?
Manufacturing is consolidated at a single campus in Verna, Goa, where Molbio produces both the Truenat instruments and the single-use, disease-specific cartridges. By vertically integrating chip fabrication, reagent filling, and software development under one roof, the firm controls production quality and cost. This structure proved critical during the pandemic, when global supply-chain disruptions slowed competitors who outsource component manufacturing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: